Wockhardt’s ZAYNICH Wins FDA Approval for Drug-Resistant cUTIs
MUMBAI, India & SHORT HILLS, N.J., May 30, 2026 Wockhardt has achieved a historic milestone with the U.S. Food...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
MUMBAI, India & SHORT HILLS, N.J., May 30, 2026 Wockhardt has achieved a historic milestone with the U.S. Food...
PRINCETON, N.J., June 1, 2026 Bristol Myers Squibb has achieved a significant regulatory milestone after the U.S. Food and...
REDWOOD CITY, Calif., May 31, 2026 Revolution Medicines has announced unprecedented results from its pivotal Phase 3 RASolute 302...
Redwood City, Calif., May 6, 2026 Revolution Medicines, Inc. announced the publication of important Phase 1/2 clinical trial data...
